Loading clinical trials...
Loading clinical trials...
A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath
Conditions
Interventions
Pexidartinib
Placebo
Locations
39
United States
Mayo Clinic
Scottsdale, Arizona, United States
University of Southern California
Los Angeles, California, United States
Stanford Cancer Center
Palo Alto, California, United States
UCLA Medical Center
Santa Monica, California, United States
Mayo Clinic Cancer Center
Jacksonville, Florida, United States
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Start Date
May 11, 2015
Primary Completion Date
March 27, 2017
Completion Date
April 30, 2021
Last Updated
May 11, 2022
NCT04635111
NCT03069469
NCT05349643
NCT04731675
NCT02471716
NCT01261429
Lead Sponsor
Daiichi Sankyo
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions